Keppra® Approved By FDA For Childhood Seizures
In the U.S., Keppra® has been approved as adjunctive therapy for partial onset seizures in adults and children aged four years and older with epilepsy. However the UCB recently announced that the U.S. Food and Drug Administration (FDA) has now approved to lower the age restriction to include infants from the age of one month and older with epilepsy. Professor Dr. Iris Loew-Friedrich, Chief Medical Officer and Executive Vice President UCB â�¨declared: â�¨”As a leader in epilepsy UCB has a responsibility to develop effective medicines that address unmet medical needs…
Health News from Medical News Today
Categories: Lymphoblastic Cancer Drugs Tags: Approved, Childhood, Keppra®, Seizures
Epileptic Seizures Linked To Significant Risk Of Subsequent Brain Tumour
Epileptic seizures can precede the development of a subsequent brain tumour by many years, suggests research published online in the Journal of Neurology Neurosurgery and Psychiatry. The risk seems to be greatest among those aged between 15 and 44 when first admitted to hospital for an epileptic seizure, the findings show…
Cancer / Oncology News From Medical News Today
Categories: Lymphoblastic Cancer Foundation Tags: Brain, Epileptic, linked, Risk, Seizures, Significant, Subsequent, Tumour
